Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01351454 · ClinicalTrials.gov registry record · NA
Behavioral Depression Treatment for African American HIV-infected Substance Users
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 61
- Enrollment target
NCT01351454: Completed NA study, sponsored by University of North Carolina, Chapel Hill.
NCT01351454 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 61 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01351454, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 61 participants
- Enrollment target
Study Summary
The objective of the current study is to test a novel, behavioral approach to treat depressive symptoms and improve HIV medication adherence and subsequent physical health outcomes among African American HIV-infected substance users residing in inner-city Washington, DC. This treatment will serve as a compliment to standard residential and follow-up outpatient substance use treatment, with the goal of reducing depressive symptoms and improving HIV medication adherence, physical health, and substance use outcomes.
Primary Outcome
The Beck Depression Inventory is a 21-item self-report measure of depressive symptoms.
Interventions
- BEHAVIORAL ACT HEALTHY
- BEHAVIORAL Nondirective Therapy (NDT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-06 |
| Phase | NA |
What the finished NCT01351454 record still lists
NCT01351454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which ACT HEALTHY is the first listed.
NCT01351454 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01351454 about?
NCT01351454 is a clinical study titled "Behavioral Depression Treatment for African American HIV-infected Substance Users". The objective of the current study is to test a novel, behavioral approach to treat depressive symptoms and improve HIV medication adherence and subsequent physical health outcomes among African American HIV-infected substance users residing in inner-city Washington, DC. This treatment will serve as...
What is the current status of trial NCT01351454?
This trial is currently completed. It is a NA study. The enrollment target is 61 participants. The study started on 2008-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01351454?
The interventions under investigation include: ACT HEALTHY (BEHAVIORAL), Nondirective Therapy (NDT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT01351454?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01351454's enrollment target sits among peer trials
61 1164th of 2000 higher than 837 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia